Celltrion’s Vegzelma (bevacizumab-adcd) biosimilar has been approved by the US Food and Drug Administration. It references Genentech’s Avastin, which first faced biosimilar competition in the US in 2019.
Celltrion’s Vegzelma Becomes Fourth US-Approved Bevacizumab
Estimated US Market Launch Date Is H1 2023
Celltrion’s Vegzelma earns a long-awaited USFDA approval. The oncology biosimilar will be up against established bevacizumab products from Amgen and Pfizer as well as recent newcomer Amneal.
